Aarti Pharmalabs Balance Sheet Health
Financial Health criteria checks 5/6
Aarti Pharmalabs has a total shareholder equity of ₹17.6B and total debt of ₹2.6B, which brings its debt-to-equity ratio to 15%. Its total assets and total liabilities are ₹25.8B and ₹8.3B respectively. Aarti Pharmalabs's EBIT is ₹3.1B making its interest coverage ratio 18.2. It has cash and short-term investments of ₹944.5M.
Key information
15.0%
Debt to equity ratio
₹2.64b
Debt
Interest coverage ratio | 18.2x |
Cash | ₹944.50m |
Equity | ₹17.57b |
Total liabilities | ₹8.25b |
Total assets | ₹25.82b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: AARTIPHARM's short term assets (₹13.5B) exceed its short term liabilities (₹6.9B).
Long Term Liabilities: AARTIPHARM's short term assets (₹13.5B) exceed its long term liabilities (₹1.3B).
Debt to Equity History and Analysis
Debt Level: AARTIPHARM's net debt to equity ratio (9.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if AARTIPHARM's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: AARTIPHARM's debt is well covered by operating cash flow (81.9%).
Interest Coverage: AARTIPHARM's interest payments on its debt are well covered by EBIT (18.2x coverage).